A Phase II Study of Regorafenib With a Lower Starting Dose in Patients With Metastatic Colorectal Cancer: Exposure–Toxicity Analysis of Unbound Regorafenib and Its Active Metabolites (RESET Trial)-Reference-Cited by-同舟云学术

A Phase II Study of Regorafenib With a Lower Starting Dose in Patients With Metastatic Colorectal Cancer: Exposure–Toxicity Analysis of Unbound Regorafenib and Its Active Metabolites (RESET Trial)

Published:2020-03 Issue:1 Volume:19 Page:13-21.e3
ISSN:1533-0028
Container-title:Clinical Colorectal Cancer
language:en
Short-container-title:Clinical Colorectal Cancer

Author:

Suzuki Takeshi,Sukawa Yasutaka,Imamura Chiyo K.,Masuishi Toshiki,Satake Hironaga,Kumekawa Yosuke,Funakoshi Shinsuke,Kotaka Masahito,Horie Yoshiki,Kawai Sadayuki^ORCID,Okuda Hiroyuki,Terazawa Tetsuji,Kondoh Chihiro^ORCID,Kato Ken,Yoshimura Kenichi,Ishikawa Hideki,Hamamoto Yasuo,Boku Narikazu,Takaishi Hiromasa,Kanai Takanori

Funder

Keio Gijuku Academic Development

Japan Society for the Promotion of Science

Publisher

Elsevier BV

Subject

Gastroenterology,Oncology

Reference21 articles.

1. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer;Loupakis;N Engl J Med,2014

2. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS;Yoshino;Ann Oncol,2018

3. A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors;Mross;Clin Cancer Res,2012

4. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity;Wilhelm;Int J Cancer,2011

5. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial;Bruix;Lancet,2017

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world dosing patterns of regorafenib for patients with metastatic colorectal cancer in Spain: the RE-SEARCH study;Clinical and Translational Oncology;2024-08-11

2. Association between albumin–bilirubin grade and plasma trough concentrations of regorafenib and its metabolites M-2 and M-5 at steady-state in Japanese patients;Investigational New Drugs;2024-03-22

3. Appropriate dose of regorafenib based on body weight of colorectal cancer patients: a retrospective cohort study;BMC Cancer;2023-12-21

4. Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology;Clinical Pharmacokinetics;2023-08-16

5. Efficacy of aluminum chloride in severe regorafenib-associated hand-foot skin reactions: a single-arm trial;BMC Cancer;2023-05-04